Hospital stocks extended losses amid regulatory scrutiny over cancer-drug markups and pharmacy practices. Despite the selloff, Jefferies maintained Buy ratings on six healthcare companies, citing target-price upside ranging from 22% to 46% and strong projected EBITDA growth through FY29.
Hospital stocks extended losses amid regulatory scrutiny over cancer-drug markups and pharmacy practices. Despite the selloff, Jefferies maintained Buy ratings on six healthcare companies, citing target-price upside ranging from 22% to 46% and strong projected EBITDA growth through FY29.
<iframe src="https://hindustansphere.com/embed/cluster/8d6c4f29e714f8bd68d57d2f92471c0fbedcec8c" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Jefferies is bullish on 6 healthcare stocks with upside potential of up to 46%. Own any?"></iframe>
